Results 151 to 160 of about 9,174 (251)

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

open access: yesAllergy, EarlyView.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov   +43 more
wiley   +1 more source

As‐Needed Versus Regular Medication Use in the Treatment of Allergic Rhinitis in the Pollen Season: A MASK‐air Study

open access: yesAllergy, EarlyView.
Using MASK‐air app data from 1042 users across 2690 weeks, this study compared the impact of regular versus as‐needed allergic rhinitis medication on symptom control and treatment satisfaction. Mixed‐effects linear regression models and sensitivity analyses revealed no significant differences between the two approaches, with results for oral ...
Bernardo Sousa‐Pinto   +38 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

open access: yesAllergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz   +22 more
wiley   +1 more source

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

open access: yesAllergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard   +12 more
wiley   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

open access: yesAndrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli   +7 more
wiley   +1 more source

Dupilumab in Cholinergic Urticaria: An Exploratory Phase 2 Investigator‐Initiated Study

open access: yes
Allergy, EarlyView.
Annika Gutsche   +15 more
wiley   +1 more source

Dry eye disease symptoms and associated risk factors in a Norwegian clinical cohort

open access: yesActa Ophthalmologica, EarlyView.
Abstract Background The relationship between dry eye disease (DED) symptoms and different demographic, clinical and lifestyle factors remains poorly understood. Norway's cold climate and dry indoor air may accelerate tear evaporation, contributing to a very high meibomian gland dysfunction prevalence, as found in multiple studies.
Mazyar Yazdani   +6 more
wiley   +1 more source

Factors Associated With Omalizumab Response in Chronic Spontaneous Urticaria: Are There Age‐Related Differences?

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated ...
Güler Yıldırım Nalbant   +14 more
wiley   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

open access: yesBritish Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy